RecruitingEarly Phase 1NCT06688305
68Ga-NI-FAPI PET/CT: First-in-human Study
68Ga-NI-FAPI PET/CT: First-in-human Study in Patients With Various Cancers
Sponsor
First Affiliated Hospital of Fujian Medical University
Enrollment
40 participants
Start Date
Aug 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
68Ga-NI-FAPI is a novel radiotracer incorporating a hypoxia sensitive nitroimidazole (NI)-moiety and a FAP-targeting. In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-NI-FAPI PET/CT in patients with different types of cancer.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria2
- Various solid tumors with available histopathological findings
- Signed informed consent
Exclusion Criteria2
- pregnant or lactational women
- who suffered from severe hepatic and renal insufficiency
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUG68Ga-NI-FAPI
Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-NI-FAPI.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06688305
Related Trials
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
NCT024796981 location
A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)
NCT073023477 locations
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
NCT0725273928 locations
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
NCT0724711019 locations
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
NCT0697959655 locations